Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 76 to 100 of 335

Guidance and quality standards awaiting development
Title	Type
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457	Technology appraisal guidance
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy TS ID 12115	Technology appraisal guidance
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492	Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]	Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]	Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]	Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146	Technology appraisal guidance
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490	Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]	Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]	Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]	Technology appraisal guidance
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]	Technology appraisal guidance
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]	Technology appraisal guidance
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]	Technology appraisal guidance

Results per page

10
25
50
All